Navigation Links
2nd Day of Testimony: Mainor Eglet Attorney Continues Questioning Teva Pharmaceuticals Vice President
Date:8/24/2011

LAS VEGAS, Aug. 24, 2011 /PRNewswire/ -- "Production of Propofol was stopped after the Chanin trial in 2010 due to public outcry," said Robert Eglet attorney for the plaintiffs. In a stunning turn in the Anne Arnold Hepatitis C trial in Clark County, Attorney Robert Eglet told the jury that production of the sedative Propofol was stopped within 3 weeks of the unprecedented $500 million verdict in the Chanin trial in May 2010. Teva Vice President, Craig Lea admits under examination by Eglet that Teva turned the lights out in their Propofol plant 21 days after last years verdict. 

(Photo:  http://photos.prnewswire.com/prnh/20110824/LA56965)

Plaintiff Anne Arnold was exposed to the virus hepatitis C when a contaminated jumbo 50mL infusion vial of the anesthesia medication Propofol was reused during a colonoscopy procedure at the Endoscopy Center of Southern Nevada on July 13, 2007. 50mL infusion vials of Propofol are meant for long tern sedation of patients, not short outpatient procedures like colonoscopies. Arnold was later diagnosed as having contracted hepatitis C. The lawsuit filed by Mainor Eglet alleges design defect, breach of implied warranty for a particular purpose, failure to properly warn by sending a Dear Health Care Professional letter and duty to monitor. 

This is the second trial following the largest notification by the Clark County Health Department that 50,000 residents of Nevada may be infected. In the complaint filed in Clark County District Court by Mainor Eglet Law Firm attorneys Robert Eglet, Robert Adams and Artemus Ham on behalf of plaintiffs Anne Arnold and spouse James Arnold -- the defendants Teva Parenteral Medicines, Inc.; SICOR Inc. and Baxter Healthcare Corporation -- are each responsible in some manner for causing injury and damages to the plaintiffs. 

Craig Lea takes the stand for day 3 of testimony on Wednesday, August 24, 10:15am.


'/>"/>
SOURCE Mainor Eglet
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Second Trial in the Largest Hepatitis C Outbreak in U.S. Begins - Mainor Eglet Law Firm Files for Plaintiffs
2. Mainor Eglet Attorney, Robert Eglet, Calls Teva Pharmaceuticals Vice President Craig Lea to the Stand in Hepatitis C Trial
3. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
4. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
5. Whistleblowers Attorney Says Pfizers Guilty Plea Today Opens New Chapter on Aggressive Enforcement of Pharma Companies
6. Relators Attorneys Comment On AtriCure/DOJ Proposed Settlement
7. Remarks as Prepared for Delivery By Attorney General Eric Holder at the AstraZeneca Settlement Announcement
8. Fort Worth Attorney Dwain Dent Comments on Final Judgment in Case That Left Hundreds of Babies Dead or Injured
9. Lead Plaintiffs Attorney In Forest Pharmaceuticals Case Says $313 Million Award Is Tip of the Iceberg of Future Off-Label Marketing Lawsuits
10. CVS/pharmacy Announces Agreements With U.S. Drug Enforcement Administration and U.S. Attorneys Offices
11. Summary Notice of Proposed Settlement, Settlement Fairness Hearing, and Motion for Award of Attorneys Fees and Reimbursement of Litigation Expenses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 Report Details What ... areas are going to grow at the fastest rates? ... assessing data, trends, opportunities and prospects. Our 190-page ... most lucrative areas in the industry and the future ... sales across the all the major categories of the ...
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... ... for Leading Companies – our new study reveals trends, ... issues and events affecting the Alzheimer,s disease therapeutics and ... answer these key questions: - How is the Alzheimer,s ...
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, ... anti-obesity drugs market is expected to grow at a CAGR ... CAGR of 38.7% in the second half of the forecast period. ... from 2016 to 2027. The market is estimated at $1,058 million ... ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Wells Pharmacy Network ... of their 503A compounding pharmacy located in Ocala, Florida. , Meeting the ... patients throughout the United States for high-quality human anti-aging and wellness compounded ...
(Date:1/19/2017)... ... January 19, 2017 , ... LabRoots ... scientists from around the world, announces the launch of its newly redesigned website. ... portal to research breakthroughs and trending news, vital information on upcoming virtual events ...
(Date:1/19/2017)... ... January 19, 2017 , ... Cosmetic Town, an online plastic ... in order to make it easier for their readers to get the information they ... impact as well as the techniques used on those particular areas. , “We are ...
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. ... of Dermatology and fellowship trained Mohs and cosmetic surgeon. After extensive dermatology research ... Li completed his internship in internal medicine at the Emory University and dermatology ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... who administered fillers that resulted in severe facial disfiguration. After four frightening years ... by doctors at UCLA Medical Center, who removed the substances in a partial ...
Breaking Medicine News(10 mins):